Mental health becomes a new trend in medical mergers and acquisitions! It is rumored that AbbVie (ABBV.US) is in talks to acquire Gilgamesh with a valuation possibly reaching $1 billion.

According to the Zh tng Cijng APP, it has been revealed by sources that AbbVie (ABBV.US) is in talks to acquire Gilgamesh Pharmaceuticals, which focuses on mental health treatments. Sources say that this potential deal could value the unlisted Gilgamesh at around $1 billion. They suggest that an announcement may be made in the next few weeks. Sources also added that negotiations are still ongoing and there is a possibility of delays or the deal falling through.